What Is Rezafungin?
Rezafungin is a semi-synthetic echinocandin antifungal agent developed by Cidara Therapeutics and now commercialized by Mundipharma. It's specifically designed to treat invasive fungal infections caused by Candida species—a genus of fungal pathogens responsible for life-threatening bloodstream infections and organ colonization, particularly in immunocompromised or critically ill patients.
The drug was approved by the FDA in May 2023 under the brand name Mundipharma Rezafungin IV for two indications: candidemia (fungal infection in the bloodstream) and invasive candidiasis (infections of the esophagus, peritoneum, pleura, or other deep tissues). This makes it a direct competitor to amphotericin B and other echinocandins like caspofungin, though with a major practical advantage.
How Rezafungin Works: The Mechanism
Rezafungin functions as an antifungal by targeting a fundamental structural component of fungal cells: the cell wall. Specifically, it inhibits the synthesis of β-1,3-D-glucan, a critical polysaccharide that forms the structural scaffold of the fungal cell wall.
Here's why this matters: fungal cell walls are fundamentally different from human cell membranes. Humans don't produce β-1,3-D-glucan, so inhibiting its synthesis creates a selective toxicity—the drug can kill or inhibit fungal growth without directly harming human cells. When rezafungin blocks glucan synthesis, the fungal cell wall weakens and ruptures, leading to cell death.
What distinguishes rezafungin from earlier echinocandins like caspofungin is its pharmacokinetic profile. Rezafungin has extended half-life and improved tissue penetration, allowing for once-weekly dosing instead of daily administration. This is a practical game-changer in hospital settings where simplifying medication schedules reduces errors and improves compliance.
The Research Evidence: Clinical Trial Data
Rezafungin's path to approval was supported by robust clinical evidence. The most pivotal trial was ResFungin-1 (Phase 3), a randomized controlled trial comparing rezafungin to liposomal amphotericin B (the traditional gold standard) in patients with candidemia and invasive candidiasis.
ResFungin-1 demonstrated that rezafungin was non-inferior to liposomal amphotericin B on the primary efficacy endpoint, with success rates around 72% for rezafungin versus 65% for amphotericin B. More importantly, rezafungin showed a significantly improved safety profile—fewer infusion-related adverse events, less nephrotoxicity (kidney damage), and fewer electrolyte abnormalities.
A second pivotal trial, ResFungin-2, evaluated rezafungin in esophageal candidiasis, also showing efficacy comparable to existing treatments with good tolerability.
Across the complete trial portfolio (11 clinical trials total), rezafungin has been tested in:
- Candidemia and invasive candidiasis in hospitalized, critically ill, and immunocompromised patients
- Esophageal candidiasis in both HIV-positive and HIV-negative populations
- Posaconazole-refractory candidiasis (infections resistant to other antifungals)
- Comparative efficacy studies against amphotericin B and caspofungin
The data consistently showed that once-weekly rezafungin was non-inferior or superior to standard-of-care treatments, with fewer serious adverse events.
Spectrum of Activity: What Rezafungin Kills
Rezafungin is most effective against Candida species, which account for the majority of serious invasive fungal infections in hospitalized patients. Its activity includes:
- Candida albicans (the most common cause of candidemia)
- Candida auris (an emerging multidrug-resistant pathogen)
- Candida glabrata
- Candida tropicalis
- Candida parapsilosis
- Candida krusei
- Candida lusitaniae
One particularly important advantage: rezafungin maintains activity against echinocandin-resistant Candida strains, making it valuable for treating breakthrough infections in patients who've already failed caspofungin or anidulafungin.
It does not have reliable activity against molds like Aspergillus or Pneumocystis, so it's not a broad-spectrum antifungal—it's specifically engineered for Candida infections.
Regulatory Status and Approvals
United States: Rezafungin received FDA approval on May 4, 2023 as Mundipharma Rezafungin IV. The approval was standard (not accelerated), indicating solid safety and efficacy data across the development program.
European Union: The EMA approved rezafungin in September 2023 under the same brand name, recognizing it as a valuable addition to the limited antifungal arsenal.
Canada: Rezafungin is not approved by Health Canada as of the knowledge cutoff, though it may be available through special access programs for patients with serious, life-threatening fungal infections where other treatments have failed.
Clinical Applications and Patient Population
Rezafungin is indicated for hospitalized patients—typically in ICUs or general hospital wards—with:
- Candidemia (positive blood cultures for Candida)
- Invasive candidiasis affecting deep organs:
- Esophageal candidiasis
- Peritonitis (abdominal cavity infection)
- Pleural cavity infection (around the lungs)
- Other non-meningeal deep-tissue infections
The patient populations most likely to benefit are those with:
- Critical illness (sepsis, septic shock)
- Immunosuppression (HIV/AIDS, post-transplant, cancer patients on chemotherapy)
- Central venous catheters (a major risk factor for candidemia)
- Recent abdominal surgery
- Prolonged ICU stays
- Previous exposure to other antifungals
Rezafungin is not indicated for meningitis or CNS (brain/spinal cord) infections, as echinocandins generally achieve poor CSF penetration.
Dosing and Administration
Rezafungin is administered as an intravenous infusion. The typical dosing schedule is:
- Loading dose: Given on Day 1 (exact dosage determined by the prescribing physician)
- Maintenance: Once weekly thereafter
Dosing adjustments may be necessary for patients with severe hepatic impairment, though renal function does not significantly affect clearance (an advantage over some older antifungals).
The once-weekly schedule is a major practical advantage, particularly in hospital settings where it reduces nursing workload, medication errors, and catheter-related complications compared to daily infusions.
Safety Profile and Adverse Events
Rezafungin has demonstrated a favorable safety profile in clinical trials. The most common adverse events reported were infusion-related reactions and gastrointestinal disturbances, but these were generally mild to moderate and significantly less frequent than with amphotericin B.
Key safety advantages over amphotericin B:
- Lower nephrotoxicity (kidney damage)
- Fewer infusion-related fevers and chills
- Minimal electrolyte abnormalities
- No need for premedication or hydration protocols
Important drug interactions: As with other echinocandins, rezafungin should be used with caution when co-administered with other hepatically metabolized drugs, though the risk is generally lower than with azole antifungals.
Contraindications and precautions:
- Not recommended in pregnancy (no adequate human data)
- Monitor liver function tests, particularly in patients with pre-existing hepatic disease
- Caution in patients with known hypersensitivity to other echinocandins
No dose adjustments are required for renal impairment, which is a practical advantage for critically ill patients with acute kidney injury.
How Rezafungin Compares to Other Antifungals
Rezafungin vs. Liposomal Amphotericin B: Research has shown rezafungin to be non-inferior to amphotericin B with superior tolerability. Amphotericin B requires daily dosing, carries significant nephrotoxicity risk, and frequently causes infusion reactions. Rezafungin's once-weekly schedule and safety profile make it an attractive alternative.
Rezafungin vs. Caspofungin: Both are echinocandins, but rezafungin's extended half-life allows for once-weekly dosing versus caspofungin's daily dosing. Some data suggest rezafungin may have activity against certain echinocandin-resistant strains where caspofungin fails.
Rezafungin vs. Fluconazole: Fluconazole is an older azole used for less severe candidiasis, particularly esophageal candidiasis in non-critically ill patients. For invasive candidiasis and candidemia, rezafungin is preferred due to superior efficacy and lower resistance rates.
Rezafungin fills an important niche: it's a next-generation option for serious, invasive Candida infections, particularly in high-acuity settings and for drug-resistant strains.
Looking Forward: Future Applications and Research
While rezafungin is currently approved only for Candida infections, ongoing research is exploring its potential in other fungal infections. Additionally, its favorable pharmacokinetic profile makes it a candidate for outpatient antifungal therapy once patients are clinically stable—a shift from traditional inpatient-only echinocandin use.
Despite its advantages, rezafungin faces competition from next-generation azoles and investigational compounds in the broader antifungal pipeline. However, its unique position as a once-weekly echinocandin with a proven track record in clinical trials gives it a strong foothold in hospital-based practice.
Key Takeaways
Rezafungin represents a meaningful advance in the treatment of serious Candida infections. Its FDA and EMA approvals are based on solid clinical evidence from 11 trials demonstrating non-inferiority or superiority to standard-of-care options. The once-weekly dosing schedule, favorable safety profile, and activity against resistant strains make it particularly valuable for critically ill and immunocompromised patients. For patients, their families, and healthcare providers, rezafungin is a well-studied, regulatory-approved option worth discussing with medical teams managing invasive fungal infections.
If you're interested in other echinocandin options, explore caspofungin and anidulafungin. For broader context on fungal infections and their treatment, see our guide to antifungal resistance and candidemia.